Bhaskar Chaudhuri
Board Member
Tarsus Pharmaceuticals, Inc. (TARS)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Bhaskar Chaudhuri
Bhaskar Chaudhuri is recorded as Board Member at Tarsus Pharmaceuticals, Inc. (TARS). Earlier roles on record: Board Member at Arcutis Biotherapeutics, Inc. (ARQT) until December 3, 2025. Arcutis Biotherapeutics, Inc. reported in an 8-K filed December 8, 2025 that Bhaskar Chaudhuri retired as chair of the Compensation Committee of the Board, effective December 3, 2025. Arcutis Biotherapeutics, Inc. reported in an 8-K filed December 8, 2025 that Bhaskar Chaudhuri retired as member of the Board of Directors, effective December 3, 2025.
“On December 3, 2025, Mr. Bhaskar Chaudhuri retired from his positions as a member of the Board of Directors (the "Board") of Arcutis Biotherapeutics, Inc. (the "Company") and chair of the Compensation Committee of the Board.”
“On December 3, 2025, Mr. Bhaskar Chaudhuri retired from his positions as a member of the Board of Directors (the "Board") of Arcutis Biotherapeutics, Inc. (the "Company") and chair of the Compensation Committee of the Board.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
2016-01-01–2025-12-03
-
2016-01-01–2025-12-03
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Tarsus Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Bobak Azamian CEO, Chairman
- Jeffrey S. Farrow CFO
- Leonard Greenstein CFO
- Seshadri Neervannan COO
- Bryan Wahl General Counsel
- Andrew Goldberg Board Member
- David E.I. Pyott Board Member
- Elizabeth Yeu-Lin, M.D. Board Member
- Katherine Goodrich Board Member
- Rosemary A. Crane Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.